No Detail Found!

Expression of CD44 and Clinicopathological Characteristics in Egyptian Patients with Acute Myeloid Leukemia

Author(s)
Samir Ali Mohamed El-Masry Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute, University of Sadat City,,Egypt
Salah Elshahhat Aref Elgendy Clinical Pathology department, Faculty of Medicine, Mansoura University,,Egypt
Hanan Abdalla Elshabrawi Mohamed Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute, University of Sadat City,,Egypt
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease as reflected by differences in the morphology of leukemic blasts, by variations in the clinical picture and therapeutic outcome, and by differences in their preceding history arising de novo or from a preleukemic state of myelodysplasia, or after treatment for another malignant disease.CD44 is an adhesion glycoprotein which helps with the homing of hematopoietic precursor cells. In AML, CD44 has been investigated as a stem cell marker, and expression of its variant proteins has been associated with poor prognosis. The aim of the present study was to bring more information regarding the relevance of CD44 expression in AML prognosis. The study carried out on 100 adult divided into: group ? included 80 newly diagnosed adults with AML and group II twenty apparently healthy adults (as control group). Each adult was subjected to complete history taking, clinical examination, laboratory investigations in the form of routine investigations; CBC, Bone marrow aspiration, Immunophenotyping, and cytogenic studies determined by Flow cytometer for routine panel of AML. Special investigations in the form of flow cytometeric analysis of CD44 expression was done for all adults. The highCD44 expression may correlate with increased AML relapse and shorter disease-free survival. In conclusion, diagnosis of AML will still depend on morphology, immunophenotyping, and, in part, on metaphase cytogenetics. However, we suggest that CD2, CD4, CD35, and CD14 can be incorporated as additional biomarkers to improve prognostication in AML, which are likely to enhance treatment efficacy in patients with AML
Publication Details
Page(s) 784-792
DOI DOI not available
Published Journal: Bioscience Research, Volume: 19, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
Acute myeloid leukemia, Immunophenotyping, Blasts, FAB, CD44
0

Citations

0

Downloads

140

Views